FUNGIZONE
LOE ApproachingNDAORALSUSPENSION
Approved
Jun 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUNGIZONE is an oral antifungal suspension approved in 1971 as an NDA by Bristol Myers Squibb. The product treats fungal infections via oral administration. Mechanism of action and specific indications are not currently documented in available data.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30/100), this brand likely operates with a small, maintenance-focused team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FUNGIZONE offers limited career expansion given zero linked job openings and approaching loss of exclusivity. Roles focus on maintaining market share and managing the transition to generic competition rather than growth initiatives.
Brand ManagerCommercial Operations Manager
Worked on FUNGIZONE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.